

EXHIBIT D-1

REVISED 10-25-2016 14:09;

INTERIM STUDY PROPOSAL 2015-188

1
2
3 REQUESTING THE HOUSE COMMITTEE ON PUBLIC HEALTH, WELFARE, AND
4 LABOR STUDY THE SUBSTITUTION OF BIOLOGIC PRODUCTS AND APPROACHES
5 BY OTHER STATES REGARDING THE PROCESS UNDER WHICH PHARMACISTS ARE
6 ALLOWED TO MAKE BIOLOGIC PRODUCT SUBSTITUTION.
7

8 WHEREAS, the Biologics Price Competition and Innovation Act was enacted
9 on March 23, 2010, to create a new abbreviated process for approval of
10 intended copies of biologic products, including biosimilars, and requires the
11 United States Food and Drug Administration to apply different considerations
12 for approval of generic products; and
13

14 WHEREAS, a biologic product is a medical product made from human,
15 animal, or microorganism cells that is intended to treat diseases and medical
16 conditions and is much more complex to manufacture than traditional
17 chemically synthesized drugs; and
18

19 WHEREAS, a biosimilar product is a biologic product that is approved
20 based on a showing that the product is highly similar to a biological product
21 that has been approved by the United States Food and Drug Administration,
22 also known as a reference product, and clinically has no meaningful
23 differences in terms of safety and effectiveness from the reference product;
24 and
25

26 WHEREAS, the United States Food and Drug Administration has approved
27 three (3) biosimilars, with more currently under review; and
28

29 WHEREAS, twenty-five (25) states have passed legislation establishing
30 state standards for substitution of biologic products; and
31

32 WHEREAS, Arkansas law contains standards for the substitution of
33 generic drugs, but does not contain a provision for the substitution of
34 biologic products; and
35

1 WHEREAS, the General Assembly should pursue all approaches to ensure
2 that the citizens of Arkansas have equal access to all medical products
3 available for use,
4

5 NOW THEREFORE,

6 BE IT PROPOSED BY THE HOUSE COMMITTEE ON PUBLIC HEALTH, WELFARE, AND LABOR OF
7 THE NINETIETH GENERAL ASSEMBLY OF THE STATE OF ARKANSAS:
8

9 THAT the House Committee on Public Health, Welfare, and Labor study the
10 substitution of biologic products and approaches by other states regarding
11 the process under which pharmacists are allowed to make biologic product
12 substitution.
13

14 Respectfully submitted,
15
16
17

18 Representative Stephen Magie
19 District 72
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 By: JMB/JMB